2,5-Disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 22, 2003, Pages 4031-4034

  Urbanski, Maud J ^a   Chen, Robert H ^a,b   Demarest, Keith T ^a   Gunnet, Joseph ^a   Look, Richard ^a   Ericson, Eric ^a   Murray, William V ^a   Rybczynski, Philip J ^a   Zhang, Xiaoyan ^a  

^a JOHNSON AND JOHNSON   (United States)

^b Ace Chemicals and Pharmaceutical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZEPINE DERIVATIVE; CARBOXYL GROUP; DIURETIC AGENT; RECEPTOR SUBTYPE; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; NONHUMAN; PROTEIN BINDING; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 0242285595     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.08.051     Document Type: Article

References (19)

1. Reeves W.B., Andreoli T.E. Wilson J.D., Foster D.W. Williams Textbook of Endocrinology, 8th ed. 1992;331-356 W. B. Saunders, Philadelphia.
2. Mayinger B., Hensen J. Exp. Clin. Endocrinol. Diabetes. 107:1999;157.
3. (a) Palm C., Reimann D., Gross P. Cardiovasc. Res. 51:2001;403.
4. (b) Paranjape S.B., Thibonnier M. Expert Opin. Investig. Drugs. 10:2001;825.
5. (c) Laszlo F.A., Laszlo F. Jr., De Wied D. Pharmacol. Rev. 43:1991;73.
6. (a) Albright J.D., Chan P.S. Curr. Pharm. Des. 3:1997;615.
7. (b) Matthews J.M., Hoekstra W.J., Andrade-Gordon P., de Garabvilla L., Demarest K.T., Ericson E., Greco M.N., Gunnet J.W., Hageman W., Hecker L.R., Look R., Moore J.B., Maryanoff B.E. Bioorg. Med. Chem. Lett. 13:2003;753 (c) Trybulski E. Doherty A.H., Hagmann W.K. Ann. Rep. Med. Chem. 2001;159-168 Academic.
8. (a) Albright J.D., Chan P.S. Curr. Pharm. Des. 3:1997;615 (b) Matthews J.M., Hoekstra W.J., Andrade-Gordon P., de Garabvilla L., Demarest K.T., Ericson E., Greco M.N., Gunnet J.W., Hageman W., Hecker L.R., Look R., Moore J.B., Maryanoff B.E. Bioorg. Med. Chem. Lett. 13:2003;753 (c) Trybulski E. Doherty A.H., Hagmann W.K. Ann. Rep. Med. Chem. 2001;159-168 Academic.
9. (a) Yamamura Y., Ogawa H., Yamashita H., Chihara T., Miyamoto H., Nakamura S., Onogawa T., Yamashita T., Hosokawa T., Mori T. Br. J. Pharmacol. 105:1992;787
10. (a) Yamamura Y., Ogawa H., Yamashita H., Chihara T., Miyamoto H., Nakamura S., Onogawa T., Yamashita T., Hosokawa T., Mori T. Br. J. Pharmacol. 105:1992;787 (b) Martinez-Castelao A. Curr. Opin. Cardiovasc. Pulmonary Renal Investig. Drugs. 1:1999;423.
11. Martinez-Castelao A. Curr. Opin. Investig. Drugs. 2:2001;525.
12. (a) Taniguchi N., Tanaka, A., Matsuhisa, A., Sakamoto, K., Kishio, H., Yatsu, T. WO 9506035, 1995.
13. (b) Tahara A., Tomura Y., Wada K.I., Kusayama T., Tsukada J., Takanashi M., Yatsu T., Uchida W., Tanaka A. J. Pharmacol. Exp. Ther. 282:1997;301.
14. Urbanski M.J., Chen R.H. WO 0132639, 2001. Chem. Abstr. 134:2001;353326. Preparation of this intermediate is described herein.
15. Robins M.J., Wnuk S.F. Tetrahedron Lett. 29:1988;5729.
16. Dhanoa D.S., Bagley S.W., Chang R.S., Lotti V.J., Chen T.B., Kivlighn S.D., Zingaro G.J., Siegl P.K., Patchett A.A., Greenlee W.J. J. Med. Chem. 36:1993;4230.
17. Chiralpak AD 5 cm×50 cm; Chiral Technologies, Inc.: 730 Springdale Dr., Exton, PA, USA.
18. The absolute stereochemistry of compound 4 was determined by crystal structure analysis of an intermediate prepared by Chemical Development at JJPRD. Hydroquinine was used as the counterion for this analysis. We would like to acknowledge Fuqiang Liu and Ann Gelormini for scale-up efforts and contributions to this project.
19. Ruffolo R.R., Brooks D.P., Huffman W.F., Poste G. Drug News Perspect. 4:1991;217.